A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies

Michael J. Koren; Peter H. Jones; Jennifer G. Robinson; David Sullivan; Leslie Cho; Thomas Hucko; J. Antonio G. Lopez; Alex N. Fleishman; Ransi Somaratne; Erik Stroes

doi:10.1007/s40119-020-00181-8

Back

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies

Journal article

Open access

Peer reviewed

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies

Michael J. Koren, Peter H. Jones, Jennifer G. Robinson, David Sullivan, Leslie Cho, Thomas Hucko, J. Antonio G. Lopez, Alex N. Fleishman, Ransi Somaratne and Erik Stroes

Cardiology and therapy, Vol.9(2), pp.447-465

06/20/2020

DOI: 10.1007/s40119-020-00181-8

PMCID: PMC7584715

PMID: 32564340

Files and links (1)

url

https://doi.org/10.1007/s40119-020-00181-8View

Published (Version of record) Open Access

Abstract

A statin is a type of medication that is used, with diet and exercise, to lower cholesterol levels and help prevent a heart attack or stroke caused by atherosclerosis. Atherosclerosis is the hardening and narrowing of blood vessels known as arteries from a buildup of plaque, usually made up of cholesterol and other fatty substances. LDL cholesterol, also known as “bad” cholesterol, is one of the most important risk factors for having a heart attack, and can be lowered. Patients with a high risk of heart disease may benefit from the additional lowering of LDL cholesterol beyond that achieved by statins alone. The medication evolocumab reduced LDL cholesterol levels and improved other risk factors more than the medication ezetimibe in four studies. These studies included patients who were receiving statins and those who were not, including those who did not receive statins because of statin-related side effects. Both evolocumab and ezetimibe had good safety profiles.

Dyslipidemia

Evolocumab

Ezetimibe

Lipid-lowering therapy

Original Research

PCSK9 inhibition

Details

Title: Subtitle: A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies
Creators: Michael J. Koren - Jacksonville Center for Clinical Research
Peter H. Jones - 6655 Travis St., Suite 320, Houston, TX 77030 USA
Jennifer G. Robinson - 145 N. Riverside Dr, Iowa City, IA 52246 USA
David Sullivan - Royal Prince Alfred Hospital
Leslie Cho - Cleveland Clinic
Thomas Hucko - Amgen (United States)
J. Antonio G. Lopez - Amgen (United States)
Alex N. Fleishman - Amgen (United States)
Ransi Somaratne - Amgen (United States)
Erik Stroes - Meibergdreef 9, 1105 AZ Amsterdam-Zuidoost, Amsterdam, The Netherlands
Resource Type: Journal article
Publication Details: Cardiology and therapy, Vol.9(2), pp.447-465
DOI: 10.1007/s40119-020-00181-8
PMID: 32564340
PMCID: PMC7584715
NLM abbreviation: Cardiol Ther
ISSN: 2193-8261
eISSN: 2193-6544
Publisher: Springer Healthcare
Grant note: ;
Language: English
Date published: 06/20/2020
Academic Unit: Epidemiology; Fraternal Order of Eagles Diabetes Research Center
Record Identifier: 9984364458702771

Metrics

29 Record Views

9 Times Cited - Web of Science